Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibody Drugs Could Be Next COVID-19 Milestone

DARPA Saw The Pandemic Coming – Can AbCellera Investment Pay Off?

Executive Summary

Working with the US agency for two years, AbCellera was primed to respond, and is competing with Vir and Regeneron to bring a COVID-19 therapy to patients before the end of 2020.

You may also be interested in...



Coronavirus Update: Lilly Initiates 2,400-Patient Nursing Home Trial

Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.

Coronavirus Update: Gilead Ready To Unveil Remdesivir Price

Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel